Quizartinib

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses how advances in the understanding of prognostic biomarkers may help guide the treatment of AML.

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses strategies for preventing relapse in patients with AML.

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses the biggest challenges in AML care today.

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses emerging and experimental therapies being researched for AML.

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses the latest advancements in treatment options for acute myeloid leukemia.

SAN DIEGO — Akriti Jain, MD, highlights presentations from ASH Annual Meeting and Exposition focused on triplet combination therapy for patients with acute myeloid leukemia.

In this edition, FDA approves Vanflyta for newly diagnosed AML; liso-cel could have ‘best shot’ at remission for double refractory CLL; mortality factors among cancer survivors and more.

The FDA approved quizartinib for use in combination with standard chemotherapy for treatment of patients with newly diagnosed acute myeloid leukemia with FLT3 internal tandem duplication mutations.

The FDA granted priority review to quizartinib for treatment of certain patients with acute myeloid leukemia.

Adding quizartinib to standard chemotherapy and up to 3 years of continuation therapy extended OS among a subset of older adults with newly diagnosed acute myeloid leukemia, according to results of the phase 3 QuANTUM-First trial.